During the first stage of the study, 23 patients were enrolled and treated with 120 mg of ARQ 197 b.i.d. To date, fourteen of these patients are evaluable for efficacy. In addition to the patient with the confirmed partial response, ten of the evaluable patients have demonstrated stable disease. Preliminary data from the first stage will be presented at the Connective Tissue Oncology Society meeting scheduled in November, 2008.
& No I don’t own any.